Last updated: March 1, 2026
Case Overview
Allergan USA, Inc. filed suit against Sun Pharmaceutical Industries Limited (Sun Pharma) in the District of Delaware on January 20, 2022, asserting patent infringement claims related to the pharmaceutical product Bimatoprost Ophthalmic Solution (marketed as Lumigan, Latisse). The case number is 1:22-cv-00182.
The core dispute involves allegations that Sun Pharma's generic version infringes on Allergan's patents related to the formulation and method of use of Bimatoprost. Allergan seeks injunctive relief and damages for patent violation.
Patent Rights and Allegations
Allergan holds multiple patents protecting Bimatoprost products, primarily U.S. Patent Nos. 8,633,562 and 9,066,943. These patents cover methods for increasing eyelash growth and specific formulations of Bimatoprost ophthalmic solutions.
The plaintiff contends that Sun Pharma's generic Bimatoprost products infringe these patents by:
- Using similar formulation techniques for eyelash enhancement.
- Packaging and delivery methods identical or substantially similar to those protected by Allergan's patents.
- Engaging in manufacturing and distribution prior to patent expiry or without proper licensing.
Procedural Posture and Motions
Allergan filed a preliminary injunction motion shortly after the complaint, seeking to prevent Sun Pharma from marketing its generic Bimatoprost until the patent validity and infringement issues are resolved.
Sun Pharma filed a motion to dismiss or for summary judgment, arguing that:
- The patents are invalid due to obviousness and lack of novelty.
- The patent claims are anticipated by prior art references.
- The product does not infringe because of differences in formulation or method.
The court held a series of hearings, and both parties submitted claims construction briefs to determine the scope of patent terms.
Key Deadlines and Events
- January 20, 2022: Complaint filed.
- February 2022: Initial case management conference.
- March 2022: Patent claim construction hearings.
- June 2022: Hearing on motion for preliminary injunction.
- July 2022: Court issued order denying preliminary injunction but allowing to proceed with discovery.
- October 2022: Expert disclosures exchanged.
- December 2022: Summary judgment motions scheduled.
Legal Issues
- Patent infringement: Whether Sun Pharma’s product infringes Allergan's patents, direct or induced.
- Patent invalidity: Whether the patents are invalid due to prior art.
- Damages and remedies: Calculation of damages if infringement is found and whether an injunction is appropriate.
Current Status
As of the latest update (March 2023), the case is in the discovery phase. No trial date has been set. The court has yet to rule on key motions: the infringement claim, validity defenses, and the preliminary injunction.
Comparative Patent Analysis
| Patent Number |
Filed Date |
Expiry Date |
Claims |
Focus |
Legal Challenges |
| 8,633,562 |
2012-04-13 |
2030-04-13 |
20 |
Formulation for eyelash growth |
Obviousness challenge filed by Sun Pharma |
| 9,066,943 |
2014-08-01 |
2032-08-01 |
15 |
Method of use |
Prior art references cited in invalidity motions |
Sun Pharma’s defenses center on prior art references such as U.S. Patent No. 5,500,200 and international publications disclosing similar formulations.
Strategic Implications
The case’s outcome influences the generics market for ophthalmic drugs, with potential impacts on market entry strategies, patent litigation tactics, and licensing negotiations. Allergan aims to enforce patent rights to delay generic competition.
Key Takeaways
- The case centers on patent infringement claims linked to Bimatoprost formulations.
- Allergan seeks to prevent Sun Pharma from launching a generic version until patent issues are resolved.
- The dispute involves complex claim construction, validity, and infringement analyses.
- The current procedural stance favors continued litigation, with no final judgments issued as of March 2023.
- The case exemplifies typical patent enforcement actions in the pharmaceutical sector.
FAQs
1. What patents are involved in this case?
The patents involved are U.S. Patent Nos. 8,633,562 and 9,066,943, covering Bimatoprost formulations and methods of use.
2. What damages are Allergan seeking?
Allergan is seeking injunctive relief and damages for patent infringement, including lost profits and reasonable royalties.
3. Has a trial date been scheduled?
No, as of March 2023, the case remains in discovery, and no trial date has been set.
4. What are Sun Pharma's primary defenses?
Sun Pharma claims the patents are invalid due to prior art and non-infringement based on differences in formulation and method.
5. Why is this case significant?
It highlights issues related to patent protection in the ophthalmic drug market and the potential for patent challenges involving complex claim interpretations.
References
[1] U.S. District Court for the District of Delaware. (2022). Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited, Case No. 1:22-cv-00182.
